Amarin reports Q2 adjusted EPS 4c vs. 1c last year

Reports Q2 revenue $72.7M vs. $67.5M last year. “The strategic actions taken in the second quarter – our partnership with Recordati to accelerate VAZKEPA commercialization in Europe and the associated global restructuring to reduce operating expenses and cash burn for the future – are significant steps to increase value for shareholders,” said Aaron Berg, President & CEO, Amarin (AMRN). “Operationally, our second quarter results reflect important progress in advancing the growth and impact of VASCEPA/VAZKEPA globally as well as our continued focus on operational efficiency and balance sheet management. The steps we have taken, combined with our performance during the quarter, position the Company for future growth, powered by our key strengths: VASCEPA/VAZKEPA, a product with proven science and significant growth potential globally; a global business with multiple efficient revenue streams; and significant financial assets, including nearly $300 million in cash and no debt. We continue to be committed to generating value from these assets and, at the same time, pursuing potential additional strategic opportunities. We are excited about the potential for this next chapter of the Amarin story and look forward to reporting on our continued progress in the future.”